Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model

Head and Neck

Volumn 33, Issue 3, 2011, Pages 349-358

  Sano, Daisuke ^a   Fooshee, David R ^a   Zhao, Mei ^a   Andrews, Genevieve A ^a   Frederick, Mitchell J ^a   Galer, Chad ^a   Milas, Zvonimir L ^a   Morrow, Phuong Khanh H ^a   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

epidermal growth factor receptor (EGFR); head and neck squamous cell carcinoma (HNSCC); targeted molecular therapy; vandetanib; vascular endothelial growth factor receptor 2 (VEGFR 2)

Indexed keywords

PACLITAXEL; VANDETANIB; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DENSITY; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM CELL; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MICROVESSEL DENSITY; MOLECULAR THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PACLITAXEL; PIPERIDINES; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951709755     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21455     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Goldberg HI, Lockwood SA, Wyatt SW, Crossett LS,. Trends and differentials in mortality from cancers of the oral cavity and pharynx in the United States, 1973-1987. Cancer 1994; 74: 565-572. (Pubitemid 24217618)
3. Baselga J,. Targeting tyrosine kinases in cancer: the second wave. Science 2006; 312: 1175-1178. (Pubitemid 43801135)
4. Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transduction. Cell 1991; 64: 281-302. (Pubitemid 121001255)
5. Thomas GR, Nadiminti H, Regalado J,. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005; 86: 347-363. (Pubitemid 41746374)
6. Artese L, Rubini C, Ferrero G, Fioroni M, Santinelli A, Piattelli A,. Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma. Anticancer Res 2001; 21: 689-695. (Pubitemid 32267594)
7. Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y,. Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma. Anticancer Res 2002; 22: 1039-1044. (Pubitemid 34836148)
8. O-charoenrat P, Rhys-Evans P, Eccles SA,. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 2001; 92: 556-568. (Pubitemid 32735191)
9. Ryan AJ, Wedge SR,. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005; 92 Suppl 1: S6-13. (Pubitemid 40897411)
10. Kerbel RS,. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312: 1171-1175. (Pubitemid 43801134)
11. Weichselbaum RR, Dahlberg W, Beckett M, et al. Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci U S A 1986; 83: 2684-2688. (Pubitemid 16026948)
12. Yigitbasi OG, Younes MN, Doan D, et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004; 64: 7977-7984. (Pubitemid 39446932)
13. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C,. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279.
14. Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ,. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 2002; 8: 293-298. (Pubitemid 34101491)
15. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546-1556. (Pubitemid 36418413)
16. Ullrich A, Schlessinger J,. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212.
17. Wells A,. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643. (Pubitemid 29248872)
18. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009; 27: 1864-1871.
19. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. (Pubitemid 43209104)
20. Cohen EE,. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2659-2665. (Pubitemid 46622087)
21. Jain RK,. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693. (Pubitemid 36749217)
22. Baillie R, Harada K, Carlile J, Macluskey M, Schor SL, Schor AM,. Expression of vascular endothelial growth factor in normal and tumour oral tissues assessed with different antibodies. Histochem J 2001; 33: 287-294. (Pubitemid 32807978)
23. Kim SJ, Uehara H, Yazici S, et al. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004; 64: 4201-4208. (Pubitemid 38802424)
24. Morelli MP, Cascone T, Troiani T, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16 Suppl 4: iv61-68. (Pubitemid 43084948)
25. Ozer E, Grecula JC, Agrawal A, Rhoades CA, Young DC, Schuller DE,. Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx. Laryngoscope 2006; 116: 607-612. (Pubitemid 44318073)
26. Nonaka M, Ikeda H, Fujisawa A, Uehara M, Inokuchi T,. Induction of apoptosis by paclitaxel in human oral carcinoma cells. Int J Oral Maxillofac Surg 2006; 35: 649-652. (Pubitemid 43863126)
27. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063. (Pubitemid 30305105)
28. Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007; 6: 471-483. (Pubitemid 46332449)
29. McCarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004; 3: 1041-1048. (Pubitemid 39295001)
30. Grant DS, Williams TL, Zahaczewsky M, Dicker AP,. Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere). Int J Cancer 2003; 104: 121-129. (Pubitemid 36184155)
31. Muta M, Yanagawa T, Sai Y, et al. Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells. Oncology 2009; 77: 182-191.
32. Sano D, Choi S, Milas ZL, et al. The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg 2009; 135: 411-420.
33. Kerbel RS,. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505-515. (Pubitemid 30137936)
34. Hammarsten P, Halin S, Wikstöm P, Henriksson R, Rudolfsson SH, Bergh A,. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 2006; 12: 7431-7436. (Pubitemid 46095418)
35. Conrad C, Ischenko I, Köhl G, et al. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs 2007; 18: 569-579. (Pubitemid 46597412)
36. Troiani T, Serkova NJ, Gustafson DL, et al. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res 2007; 13: 6450-6458. (Pubitemid 350075035)
37. Sano D, Kawakami M, Fujita K, et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 2007; 17: 289-295.
38. Gustafson DL, Frederick B, Merz AL, Raben D,. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 2008; 61: 179-188. (Pubitemid 350160317)
39. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009; 27:abstr CRA8003.
40. Papadimitrakopoulou V, Frank SJ, Blumenschein GR, et al. Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009; 27:abstr 6016.